NCT07409831Recruiting
Incretin-based Therapies, Nutrition, and Physical Activity
Holistic Approach to Cardiometabolic Health and Obesity: Incretin-based Therapies, Nutrition, and Active Lifestyle
Source: ClinicalTrials.gov · Last updated 16 Jul 2026
Brief summary (registry, in English)
The goal of this clinical trial is to evaluate whether combining a six-month structured lifestyle intervention (physical activity and nutrition) with incretin-based weight-loss medication improves preservation of muscle mass and physical function in adults living with obesity, compared with medication alone, and to assess the feasibility of a collaborative hospital-community care model. This one-year pilot study will recruit 120 adults aged 18-70 years with obesity (BMI ≥30 kg/m² or ≥27 kg/m² with at least one comorbidity) receiving routine obesity care at the Institut universitaire de cardiologie et de pneumologie de Québec - Université Laval. All participants will initiate physician-prescribed incretin-based therapy as part of standard care. The intervention group will receive medication plus a six-month structured lifestyle program delivered in collaboration with an exercise facility, including supervised strength-focused exercise and bi-monthly nutrition counseling, followed by a six-month consolidation phase. The control group will receive medication alone. Outcomes will be assessed at baseline and at 3, 6, and 12 months. Participants will be randomly assigned in a 1:1 ratio to either the medication-only group or the combined medication and lifestyle intervention group. Participants randomized in the medication only group will receive a personalized consult with both a registered dietician and kinesiologist at the end of the study.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 120 (estimated)
- First submitted
- 28 Jan 2026
- Start date
- 6 Jul 2026
- Primary completion date
- Mar 2028
- Lead sponsor
- Laval University
- Diseases
- Obesity
- NCT number
- NCT07409831
What you commit to
- Study type: Interventional
- Planned participants: 120
- From 6 Jul 2026 to the primary completion date, Mar 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior or ongoing incretin-based therapy or history of bariatric surgery
Other illness
- Medical contraindications to physical activity practice (e.g., unstable cardiovascular disease, severe orthopedic limitation)
- Chronic conditions affecting protein metabolism or nutrition (e.g., advanced kidney disease, active cancer)
Other
- Pregnancy, current breastfeeding or planned pregnancy during the study period
- Implemented medical devices (e.g. pacemaker, defibrillator)
Who the study is looking for
- Adults aged 18 to 70 years
- Prescribed, but not yet initiated, incretin-based pharmacotherapy \[e.g., GLP-1 receptor agonist or dual GIP/GLP1 agonist\] living with obesity, defined as:
- BMI \>30 kg/m2, or
- BMI \>27 kg/m2 with presence of comorbidities (e.g., type II diabetes, hypertension, hypercholesterolemia)
Age in the registry: 18 years to 70 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Institut Universitaire de Cardiologie et de Pneumologie de Quebec-Université Laval Coordinator of this site? Confirm its status | Québec | Canada | Not yet recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.